TL;DR
A study presented at the 2026 EADV Congress found nail disorders were more commonly reported by people taking GLP-1 medications than by nonusers with obesity and/or type 2 diabetes. Nail detachment and discoloration remained more frequent after some adjustments, but the cross-sectional findings show an association, not proof that the drugs caused the changes.
A multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 found that people taking GLP-1 medications reported fingernail problems more often than a comparison group with obesity and/or type 2 diabetes who had never taken the drugs. Among medication users, 39% reported nail detachment, compared with 9% of nonusers; the researchers said the findings show an association, not that the medications caused the changes.
The study included 575 GLP-1 users and 1,329 nonusers recruited in France, the United States, Brazil and Mexico. Overall, 66% of users reported at least one nail disorder, compared with 53% of the comparison group. Nail discoloration was reported by 46% of users and 17% of nonusers.
The researchers said nail detachment—when a nail separates from the skin beneath it—was reported more than four times as often among users in the unadjusted comparison. After accounting for factors including existing skin conditions and nutritional deficiencies, the differences narrowed, but detachment and discoloration were still approximately two to three times more common among users, according to the report.
About half of the medication users said they had experienced nail problems before starting treatment. The study also found more reported hair and scalp symptoms among users, including hair loss and scalp redness. Those findings come from a companion analysis of the same participants; they do not establish that the drugs caused either the hair or nail symptoms.
Nail Symptoms May Need Clinical Attention
The results add a controlled comparison to an issue previously described mainly in individual reports of possible adverse reactions. They may help clinicians and patients recognize and discuss nail changes during treatment, particularly because the reported differences persisted after the researchers accounted for some relevant factors.
For people taking GLP-1 drugs for type 2 diabetes or weight management, the report is not a reason to stop medication without medical advice. The researchers said the symptoms are often benign and encouraged patients who notice nail changes to raise them with a clinician. The study does not establish how often these problems are caused by treatment, whether they resolve, or which patients may be more likely to experience them.
What the Study Compared
GLP-1 receptor agonists—including medications sold under names such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza and Trulicity—are used in the management of type 2 diabetes and, for some products, weight management. They act on a hormone signaling system involved in blood sugar and appetite regulation. Their growing use has prompted researchers to examine possible effects beyond those treatment goals.
According to the report, this was the first controlled study to investigate a possible relationship between GLP-1 medications and nail health. Participants were compared based on medication use; they were not followed over time to establish whether symptoms began after treatment or changed as treatment continued. The study’s comparison group also had obesity and/or type 2 diabetes, conditions that may themselves relate to health and nutrition.
“Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.”
— Dr. Charles Taïeb, study author
Cause and Timing Remain Unresolved
The study was cross-sectional, meaning it compared participants’ reported experiences at a point in time rather than tracking them before and after starting medication. It cannot establish whether GLP-1 treatment caused nail detachment or discoloration, or whether symptoms developed after treatment began. The fact that about half of users reported nail problems before treatment further complicates interpretation.
Weight loss alone did not fully account for the differences: the report says nail problems remained more common among users when the analysis was limited to participants who had lost weight. Still, that does not identify another cause. Some group differences also became smaller after adjustment for skin conditions and nutritional deficiencies. The available report does not provide evidence about how symptoms change over time, their severity, or whether specific drugs carry different risks.
Discuss Changes With a Clinician
The report does not describe a planned follow-up or a next study milestone. Further research that follows patients over time would be needed to clarify whether symptoms begin after treatment, how they develop, and how much of the association may relate to medication, weight changes or other health factors.
In the meantime, the study authors recommend that people taking GLP-1 medications mention nail detachment, discoloration or other changes to their doctor. They specifically caution against stopping an effective treatment on one’s own. A clinician can review the timing of symptoms and consider other possible explanations, including existing skin conditions or nutritional issues.
Key Questions
Does the study prove GLP-1 drugs cause nail detachment?
No. It found an association between medication use and reported nail problems, but its cross-sectional design cannot establish that the drugs caused them.
How common was nail detachment in the study?
Thirty-nine percent of GLP-1 users reported nail detachment, compared with 9% of nonusers in the study’s initial comparison. The figures are participant reports, not proof that treatment caused the symptom.
Were other nail problems reported?
Yes. Nail discoloration was reported by 46% of users and 17% of nonusers. At least one nail disorder was reported by 66% of users, compared with 53% of nonusers.
Should someone stop taking a GLP-1 medication if their nails change?
The study authors said not to stop an effective treatment on one’s own initiative. They advise discussing nail changes with a doctor, who can assess symptoms and other possible causes.
Source: rss
